OMass Therapeutics’ Post

We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #8.     We are collaborative: People at OMass are open and enjoy a highly collaborative environment. We expect transparency from each other and from the company, and value information-sharing to keep our collective eyes on our overall goals. We are receptive to everyone’s diverse ideas and opinions, and assume people have good intentions when they offer viewpoints or feedback. When we need to have challenging conversations, we face them together and with a candor that ensures productive resolution.    Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf    #innovation #biotech #drugdiscovery 

We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #5. We are responsible: We take personal and collective responsibility for delivering our shared goals. We hold ourselves and each other accountable – to our patients, colleagues, investors, as well as our work and mission. We apply the necessary rigor to ensure high quality. We are self-motivated and rely on each other to operate and perform at the highest levels. Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery

We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #6. We are focused: To ensure alignment with our mission, we take a focused approach to our delivery. We wisely utilise our resources and pay attention to our priorities. We balance pursuing our ambitious goals and innovations with our ability to ”focus and finish”. We focus on our most important work, and we are clear on our daily priorities to deliver our collective goals and mission. Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery

We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #2. We have resilience of spirit: When we hit a stumbling block, our ingenuity helps us remain agile and allows us to find new ways towards our goals. In the spirit of continuous learning and improvement, we accept that not everything will work first time, and we learn from any failures. Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery

Early Bird rates for Bio€quity Europe ends Friday - register now to save! With 60+ biotechs already confirmed to present, this year’s event in San Sebastián is expected to sell out, again. In fact, we are on track to exceed last year, when 300 VCs, 330 CEOs, and 150 C-level executives joined. This year we will gather in Basque Country to discuss how biotechs can rise above the noise to attract the right investors, partners, and talent. I hope you will join BioCentury Inc., EBD Group, and Regional Host Committee Chair Ysios Capital in one of the culinary capitals of the world. Register for #BioEquityEurope by Friday to save: https://ow.ly/lkOl50QyYeS Learn more, including the schedule-at-a-glance and presenting companies you will meet: https://ow.ly/8B5c50QyYeR #biotech #biopharma

Last week our insightful US Gateway panel saw Tom discussing landing and expanding as a Biotech in the US with panellists Kenneth Duncan and Ashley Jones 🇺🇸 In the clip below the panel starts off by discussing the differences between the US and European working culture and how they might be different from initial expectations. Head to our US Gateway page to watch the full webinar and to learn more about how we can support you if you plan to expand your Biotech into the US market: https://lnkd.in/eby_npzb #US #USMarket #USExpansion #USGateway #Panel #Biotech #Culture

Pricing and Market Access (P&MA) is no longer an afterthought but a critical determinant of a product's success. Learn how to develop a robust P&MA strategy that drives both commercial success and patient outcomes in this second webinar of our Biotech growth series on "Navigating the path from innovation to market success"! This webinar is specifically geared towards smaller / mid-sized biotechs and will cover: 1) Insights into state-of-the-art P&MA decision making from start to finish and the key steps to ensure global P&MA success 2) Techniques for navigating the tradeoff between price, reimbursement, and physician uptake to optimize your revenue potential 3) Current and crucial global P&MA trends (e.g., IRA/PDAP in the US, EU JCA) and their implications for your strategy development and required skillset I look forward to seeing you on Oct 16!

One company optimizing protein conjugates, one company screening for optimal efficacy and therapeutic window of protein conjugates. Well played, #RESIBoston2024 #ADCs #startup #proteinconjugation

Enjoyed the insightful comments from the panel I moderated at Biotechnology Innovation Organization CEO & Investor Conference in NY City about 'Recognizing the Patterns in Strategic M&A During Down Markets.' Special thanks to our fantastic panelists Anna Kazanchyan, M.D., Founder and CEO of Saghmos Therapeutics, Mayukh Sukhatme, MD, CEO and Chief Investment Officer of Roivant Sciences, Kipchirchir (Kip) Bitok, Ph.D. of Chardan and Chadé Severin of Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates. Take away messages: 1. The financing conditions are improving but we are not there yet. 2. Biotechs need to refocus their resources and energy on their lead asset, and prioritize product over platform. 3. Need to be patient with the IPO market in 2024. 4. Good science will be funded but not at the valuation one may hope. 5. Fed's decision to start tapering may be the psychological trigger the markets may be watching out for. #BIOCEO24 #BIOCEOConference #Biotech #Innovation #BIO2024 

Are you attending #BIO2024? Alvaro Suarez, Vice President of Business Development at Shionogi Europe, is looking forward to meeting with people who are enthusiastic about advancing innovation in patient care across Europe. If you’re keen to discuss potential partnerships you can connect with Álvaro S. and look out for him and his colleagues! #InfectiousDisease #RareDisease #PharmaPartnering #PharmaInnovation #BusinessPartnering #BioInternational2024